<DOC>
	<DOCNO>NCT00366249</DOCNO>
	<brief_summary>The purpose study look safety effectiveness once-daily dose tigecycline compare ertapenem treatment diabetic foot infection . The co-primary efficacy endpoint meet .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Once-daily Dose Tigecycline v Ertapenem Diabetic Foot Infections ( DFI ) With Substudy Patients With Diabetic Foot Infections Complicated Osteomyelitis .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Osteomyelitis</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Main inclusion criterion : Men woman age 18 old diabetes qualify foot infection . People evidence diabetic foot infection osteomyelitis may qualify osteomyelitis substudy arm . Main exclusion criterion : People additional significant disease , infection resistant pathogen , contraindication , hypersensitivity test article relate antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Diabetic foot infection</keyword>
	<keyword>Osteomyelitis</keyword>
	<keyword>Diabetes Complications</keyword>
	<keyword>Foot ulcer</keyword>
	<keyword>Skin infection</keyword>
</DOC>